|
Delayed
Saudi Arabian S.E.
05:37:28 2026-11-05 EST
|
5-day change | 1st Jan Change | ||
| 64.90 SAR | +2.61% |
|
+5.72% | +1.82% |
| 11-04 | Avalon Pharma's Q3 Attributable Net Profit, Revenue Rise | MT |
| 10-11 | Avalon Pharma Signs 10-year Licensing Agreement With OneSource Specialty Pharma | MT |
Chart: Technical Analysis
Saudi Arabian S.E.SAR
| Markets | Quality | ||
|---|---|---|---|
Saudi Arabian S.E.
| 4016 | Delayed |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 64.15 | 68 | 69.2 |
| Spread/Res. | +0.86% | -4.85% | -6.50% |
| Spread/Supp. | +14.61% | +14.61% | +16.49% |
| Support | 56.45 | 56.45 | 55.54 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- 4016 Stock
- Charts Middle East Pharmaceutical Industries Company
Select your edition
All financial news and data tailored to specific country editions
